Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Genitourinary 3Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 46Specimen Handling 42Nivolumab 30pembrolizumab 29enzalutamide 28Gemcitabine 24Docetaxel 24apalutamide 20Prednisone 20Biopsy 19cabozantinib 17Abiraterone Acetate 17enfortumab vedotin 15Androgen Antagonists 15abiraterone 14Cisplatin 14darolutamide 13Radiotherapy 13Pluvicto 12Ipilimumab 12Mitomycin 11olaparib 10atezolizumab 10X-Rays 10erdafitinib 9cabazitaxel 9Radiation 9Carboplatin 9belzutifan 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
dehydroftorafur × Genitourinary × 30 days × Clear all
NCT06770582 2026-06-11

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡